Hua Shen Group intends to raise more than 300 million planting "37" into a bright spot

Hua Shen Group (000790, closing price of 10.73 yuan) today announced the eighth session of the Board of Directors 35th meeting, the company intends to raise more than 275 million yuan for investment in technological expansion and new drug research and development projects, Licatin Project, Animal Biotechnology extension and 37 planting base construction and reserve projects. The amount of funds raised in this issue does not exceed the requirements of the above projects.　　After the collection of funds in place, such as the actual amount of funds collected less than the above-mentioned project needs, the lack of funds raised by the company to solve the self-financing. The initial set of additional price 8.92 yuan/shares this non-public issue of the object for the Securities Investment fund Management company, securities companies, investment trusts, financial companies, insurance institutional investors, qualified foreign institutional investors, other domestic legal investors and natural persons, such as not more than 10 in line with the CSRC and other relevant laws,　　A specific object specified by statute. The benchmark date for the private issue of shares is the eighth session of the Board of Directors 35th meeting resolution Notice Day, that is, June 5, 2010, the issue price is not less than the benchmark date of 20 trading days of the company's stock transactions 90%, that is, not less than 8.92 yuan/share.　　The number of non-public offerings does not exceed 32 million shares (including 32 million shares), the number of specific issues will be brought to the General Assembly to authorize the company's board of directors and sponsors (the main underwriter) to determine the consultation. The raise funds to four projects, is the Hua Shen Group of pharmaceutical companies to upgrade the technical transformation and expansion of new drug research and development projects, the Chinese god of biotechnology extension projects and Licatin in-depth research projects, bio-technical transformation of Animal Biotechnology extension project, 37 planting base construction and reserve projects, the initial estimate of investment of 135 million yuan, 65 million yuan,　　45 million yuan and 30 million yuan, totaling 275 million yuan. Among them, the biggest investment is the Hua Shen Group of pharmaceutical Plant Technical transformation expansion and new drug research and development projects. Hua Shen Group Pharmaceutical Factory is a subsidiary of the Hua Shen Group, mainly for the mixture, capsules, granules, tablets, moxibustion, dry suspension, raw materials production, the main products have nasal yuan Shu oral liquid/capsule, Vitality su oral liquid, 37 Tong Shu capsules. The project is to be in the High-tech Industrial park in Chengdu, China-shen Hi-tech industry parks for Technical transformation, the project will form the annual treatment of 4500 tons of Chinese herbal medicines, annual output of 100 million tablets, annual output of 800 million capsules, 100 million bag granules, annual output of 75 million oral liquid production capacity　　, the project also involved three new product research: Five Dragon granules in the third phase of clinical study, the Red PU granule two phase, the third phase clinical study and 37 Tong Shu Enteric Pellets capsule study.　　Panxi Construction "37" planting base 37 is the latest in the medicinal herbs market, one of the largest price increases, the Chinese god Group of the four major fund-raising investment, there are 37 planting base construction and reserve projects. Hua Shen Group said that the Panxi region of Sichuan, and Wenshan with latitude, geographical similarity, the company from 2004 to 2009 in Panxi, Sichuan, 37 introduced experiments planted and enlarge the planting work, from Wenshan in Yunnan province to introduce 37 seed and planting technology, seedling test and field shiftPlanting, observing the growth and development of 37 and the characteristics of biological expression, as well as the change of yield and quality after amplification. The use of the technology of origin combined with local practice to carry out planting work, through more than 6 years of exploration and efforts, has achieved the desired goal, in the Panxi area 37 technology feasible, the content reached the Pharmacopoeia standard, per MU yield to the level of wenshan cultivation, and according to the Gap specification requirements set up a comprehensive planting　　For large-scale cultivation and promotion has laid a solid foundation and technical reserves. The company intends to invest in Panxi in Sichuan province to build 37 scale planting base. The planting base is intended to adopt the "Company + base + farmers" approach, by the Hua Shen Group Pharmaceutical Factory leased land, the independent construction 37 medicinal herbs Planting Demonstration Base 2200 mu, of which 37 varieties seedling Base 200 mu, 37 production Base 2000 MU, starting from the third year annual output of 37 drugs 210 tons, annual output "37 flower" 20 tons.　　In addition, due to the limited capacity of the base, in order to ensure the Chinese God Group 37 pharmaceutical supplies, will be phased in the use of some of the funds reserve 37 of medicinal herbs. Hua Shen Group said that the company's 37 Tong Shu capsules in recent years, the sales scale continues to grow significantly, has become the pillar of the Group factory production. From the strategic development of the product consideration, the company needs to establish a 37 medicinal plant base, which protects 37 raw material supply stability, is conducive to the control and stability of 37 prices, reduce production costs, 37 Tong Shu capsules to create better economic and social benefits lay a solid foundation.